Lamivudine Tablets — Class III drug recall D-1847-2019
Terminated recall by American Health Packaging, reported 2019-09-18, distributed nationwide. Labeling: Incorrect or Missing Package Insert; an error in the Dosage Forms and Strengths section of the inser
| Recall number | D-1847-2019 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | American Health Packaging, Columbus, OH, United States |
| Recall initiated | 2019-08-27 |
| Classified | 2019-09-06 |
| Reported by FDA | 2019-09-18 |
| Terminated | 2020-09-09 |
| Distributed | Nationwide (US) |
| Quantity | 60 cartons |
| Reason classes | labeling |
| NDC | 60687-0362-11, 60687-0362-21 |
| Lot numbers | 186509, 186982 |
| Expiration dates | 2021-06-30 |
Product
Lamivudine Tablets, USP, 150 mg, 30 (3x10) count Unit Dose Blisters Carton, NDC 60687-362-21 (Individual Dose NDC: 60687-362-11), Distributed by American Health Packaging, Columbus, OH
Reason for recall
Labeling: Incorrect or Missing Package Insert; an error in the Dosage Forms and Strengths section of the insert that incorrectly lists the tablet description coding for the tablets.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1847-2019. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.